Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression ofmiR-99b, -144, -210, -222, -302а and -377 in tumor tissue.

Abstract

Renal cell carcinoma (RCC) is one of the most common solid tumors in adults highly resistant to conventional therapies. The expression profile of a number of miRNAs correlates with RCC response to chemotherapeutic agents. To identify the association of tumor miRNAs expression with neoadjuvant treatment response in patients with RCC. We analyzed the expression levels of tumor miR-99b, -144, -155, -210, -222, -302а, -377in 93RCC patients who received pazopanib or sunitinib in neoadjuvant regimen using RT-PCR. RNU48was used as a reference miRNA. The levels of expression of miR-99b and -377are associated with the RCC response to pazopanib, and microRNA-210and -377to sunitinib. The characteristic expression profile of miR-99b, -144, -222, -377, and miR-302a determined in 90% of cases was delineated in pazopanib responders as opposed to nonresponders. Similarly, the characteristic expression profile of miR-210, -222, -302aand -377was suggested for sunitinib responders. Levels of miR-99b, -210and -377expression in RCC tumor tissue might be used as a basis for future predictive panel intended for the assessment of the sensitivity to the regimens of neoadjuvant RCC treatment.